Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)GlobeNewsWire • 06/27/22
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)PRNewsWire • 06/27/22
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/09/22
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated MilestonesGlobeNewsWire • 05/09/22
Is a Surprise Coming for Sutro Biopharma (STRO) This Earnings Season?Zacks Investment Research • 05/05/22
Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022PRNewsWire • 04/08/22
Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/05/22
Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADCPRNewsWire • 03/30/22
Sutro Biopharma, Inc. (STRO) Moves 6.4% Higher: Will This Strength Last?Zacks Investment Research • 03/21/22
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 MilestonesPRNewsWire • 02/28/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRONewsfile Corp • 02/04/22
SHAREHOLDER ALERT: Investigation of Sutro Biopharma, Inc. Announced by Holzer & Holzer, LLCNewsfile Corp • 01/18/22
Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare ConferencePRNewsWire • 01/06/22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian CancerPRNewsWire • 01/05/22
Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater ChinaPRNewsWire • 12/27/21
Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian CancerPRNewsWire • 12/27/21
Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021PRNewsWire • 12/13/21